skip to Main Content


Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."


CY 2022 Physician Fee Schedule Proposed Rule Summary

On July 13, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

read more

Congress Considers Extension of Telehealth Flexibilities Post-Pandemic

The COVID-19 pandemic forced Congress and the Centers for Medicare & Medicaid Services (CMS) to…

read more

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/21: Research Grant Cycle
Learn more

02/22/22: Deadline For Call For Proposals
Learn more

04/01/22: Fellow Exam Application Deadline
Learn more

06/01/22: Research Grant Cycle
Learn more

06/26/22: Membership Application Deadline to be eligible for AAOA Member rate for the 2022 Basic Course

08/01/22: Scientific Abstract Submission Deadline

09/01/22: Membership Application Deadline to be voted in at the 2022 Annual Meeting


The live stream of the 2021 AAOA Annual Meeting concluded on October 21st, but you can still register and earn CME/MOC credits. 4 hours of Pre-Work On-Demand content will be accessible until November 15, 2021. If you missed a lecture during our live-streamed content, do not worry. Most of the lectures will be available within the next week until November 15, 2021. Learn More


Available Now

IFAR Impact Factor: 2.454


IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2021 AAOA Annual Meeting
Pre-launch Mid-September
On-Demand Access Closes on November 15
Learn More and Register

2022 AAOA Advanced Course
In-Person!!! Santa Fe, NM
January 13-15, 2022
Learn More and Register

2022 AAOA Basic Course
The Diptomat Beach Resort, Hollywood, FL
June 30-July 2, 2022

USP 797 Online Module
Learn More and Register

News and Updates

A Message From The AAOA President Michael Platt, MD, FAAOA

read more

United Agrees To Give Physicians ERISA Rights in Connection with Repayment Demands

Bottom line Recent class action settlement gives all out-of-network (“ONET”) physicians important – and often overlooked –…

read more
College Allergy Symptoms Treatment Back to Shcool


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>



By Anna Butrymowicz, MD

Allergy Immunotherapy (AIT) is an option for patients with allergic rhinitis (AR), allergic asthma and atopic dermatitis.  In the United States, AIT is offered in two forms, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) via tablet or drop.  The choice to pursue AIT is one that should be made after thorough discussion with your Otolaryngologist and is normally considered in patients with the above diagnoses who have failed to improve with medical management or cannot tolerate medical management, and avoidance of known allergens is not possible.  When deciding between form of AIT (SLIT vs SCIT), a number of things should be considered, including efficacy, cost, compliance, and safety.  

Efficacy: the jury is still out.  While large Cochrane reviews suggest superiority of SCIT, there are only a few randomized control trials, and these head to head analyses show equivalent benefit in regard to symptom control and medication use (with exception of 1 RTC which shows superiority of SCIT).  

Cost: This question is addressed directly in the article Hidden Costs of AIT. Overall, aqueous SLIT is considered off label by the FDA and incurs out of pocket costs.  The direct cost of SLIT tablets or co-pays for SCIT depend on insurance coverage.  There is also indirect cost to parking, travel time, missed work/school when pursuing SCIT.  

Compliance: It seems reasonable to assume that patients would be more compliant with medication they could administer at home, like SLIT, but studies show conflicting evidence, some with higher compliance with SCIT, other with higher compliance with SLIT.  Like with every other broad characterization, we have to keep individual patient characteristics/goals in mind, and tailor each treatment plan to the patient.  

Safety: SLIT has a superior safety profile, with no history of reported fatalities and a rare incidence of anaphylaxis.  In general, SCIT is well tolerated, but there have been reported fatalities and the incidence of anaphylaxis is higher.  

Generally, these are the main factors we should consider when discussing AIT with our patients, but this is not a comprehensive list.  And while SCIT and SLIT are the forms of AIT offered in the United States, the field of Otolaryngic Allergy continues to innovate, and we may see new options in the future.  Stay tuned! 

Back To Top